Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564822 | 0.87 | DHFR (0.48) | DHFRTLR8TLR7 | |
| SCHEMBL4519499 | 0.78 | TSHR (0.44) | DHFRTLR8TLR7 | |
| SCHEMBL18109747 | 0.77 | DHFR (0.69) | DHFR | |
| SCHEMBL823730 | 0.77 | TSHR (0.43) | DHFRTLR8TLR7 | |
| SCHEMBL20134736 | 0.73 | DHFR (0.67) | DHFR | |
| SCHEMBL4534010 | 0.72 | TSHR (0.46) | TLR8TLR7NOS1 | |
| SCHEMBL4516860 | 0.72 | MAPT (0.41) | TLR8TLR7NOS1 | |
| SCHEMBL4528643 | 0.72 | TSHR (0.39) | TLR8TLR7 | |
| SCHEMBL4527664 | 0.72 | TSHR (0.42) | DHFRTLR8TLR7NOS1 | |
| SCHEMBL3613491 | 0.71 | SQOR (0.45) | DHFRTLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | DHFR 13/4885TLR8 1791/4885TLR7 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.